Choi SH(1), Yoon HI(1), Kim SH(2), Kim SK(3), Shin KH(2), Suh CO(1).
(1)Dept of Radiation Oncology, Yonsei Cancer Center, Yonsei Universiy College of Medicine, Seoul, South Korea.(2)Dept of Orthopedic Surgery, Yonsei Cancer Center, Yonsei Universiy College of Medicine, Seoul, South Korea (3) Dept of Pathology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Publication
PLoS One
Summary
Herein, we describe our updated institutional experience with radiotherapy(RT) to treat fibromatosis. Forty-seven patients with fibromatosis received RT between 1990 and 2015, and were followed for 12+ months. Eight patients received RT for gross tumors, and 39 received postoperative RT after single/multiple prior surgeries. Seven recurrences were noted, including 2 in-field, 4 marginal, and 1 out-field, after a median follow-up of 60 months. On multivariate analysis, a CTV margin 5 cm and dose >45 Gy were significant predictors of non-recurrence (p = 0.039 and 0.049, respectively). Subgroup analysis showed that patients with both an CTV margin 5 cm and a dose >45 Gy showed a favorable outcome. RT is a valuable option for treating aggressive fibromatosis; doses >45 Gy and a large field produce optimal results. For in-field control, a higher dose is more necessary for gross residual tumors than for totally excised lesions.
Stay Up to Date as We Uncover More About Desmoid Tumors
